Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype
ASH 2014 - CLL
,
ASH Highlights
Conference Correspondent
— January 13, 2015
Read Article
Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study
ASH 2014 - CLL
Conference Correspondent
— January 13, 2015
Read Article
Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
ASH 2014 - Castleman's Disease
,
ASH Highlights
Conference Correspondent
— January 9, 2015
Read Article
Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma
ASH 2014 - Castleman's Disease
,
ASH Highlights
Conference Correspondent
— January 9, 2015
Read Article
Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma
ASH 2014 - Castleman's Disease
,
ASH Highlights
Conference Correspondent
— January 9, 2015
Read Article
Page 33 of 44
30
31
32
33
34
35
36
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma